All relevant data are within the paper.

Introduction {#sec001}
============

While many genes have been discovered that underlie Mendelian forms of sensorineural hearing loss (<http://hereditaryhearingloss.org/>), most cases of conductive hearing loss, often caused by otitis media and tympanosclerosis, have complex and poorly understood etiologies. Otitis media is an inflammation of the middle ear and is among the most common childhood illnesses. Heritability studies have shown that genetic factors can play an important role in otitis media susceptibility, but few contributing genes have been identified in human populations \[[@pone.0168159.ref001]\]. In contrast to human studies, a growing number of mouse mutations have been identified that manifest a high incidence of otitis media, including *Eya4*, *Tlr4*, *p73*, *MyD88*, *Fas*, *E2f4*, *Plg*, *Fbxo11*, *Evi1* \[[@pone.0168159.ref001],[@pone.0168159.ref002]\], *Sh3pxd2b* \[[@pone.0168159.ref003]\], *Rpl38* \[[@pone.0168159.ref004]\], *Isl1* \[[@pone.0168159.ref005]\], *Chd7* \[[@pone.0168159.ref006]\], *Lmna1* \[[@pone.0168159.ref007]\], *Phex* \[[@pone.0168159.ref008]\], *Oxgr1* \[[@pone.0168159.ref009]\], *Tgif1* \[[@pone.0168159.ref010]\], and *Mcph1* \[[@pone.0168159.ref011]\]. The wide diversity of these genes and their mutant pathologies, including craniofacial abnormalities with Eustachian tube malformations and innate immune response defects, underscores the complex nature of otitis media.

Here we report on the conductive hearing loss associated with a recessive ENU-induced missense mutation of the ectonucleotide pyrophosphatase/phosphodiesterase 1 gene (*Enpp1*) that was discovered at The Jackson Laboratory and named \"ages with stiffened joints\" (*asj*) because of the progressive ankylosis and osteoarthritis exhibited by mutant mice \[[@pone.0168159.ref012]\]. The *Enpp1* gene encodes an enzyme (ENPP1) that regulates soft-tissue calcification and bone mineralization by producing inorganic pyrophosphate, a major inhibitor of calcification. A previous analysis of *asj* mutant mice found that enzymatic activity of ENPP1 in the liver and inorganic pyrophosphate (PPi) levels in plasma were markedly reduced \[[@pone.0168159.ref013]\]. Other mouse mutations of *Enpp1* have been reported, including the naturally occurring \"tiptoe walking\" (*ttw*) nonsense mutation \[[@pone.0168159.ref014]\], an ENU-induced C397S missense mutation \[[@pone.0168159.ref015]\], and a genetically engineered knockout mutation \[[@pone.0168159.ref016]\]. The *Enpp1* mutant mice in these studies exhibited extensive mineralization defects in a number of tissues, including spinal ligaments, long bones, articular cartilage, heart, aorta, arterial blood vessels, vibrissae, liver, kidneys, and retina. The effects of the *Enpp1* mutations on auditory function and middle and inner ear histology of mice, however, were not examined.

We show here that *Enpp1*^*asj*^ mutant mice exhibit a conductive hearing loss that is associated with middle and inner ear mineralization abnormalities. These mice provide a new animal model for studies of otitis media and tympanosclerosis and for the hearing loss recently shown to be associated with human *ENPP1* mutations causing generalized arterial calcification of infancy and hypophosphatemic rickets \[[@pone.0168159.ref017],[@pone.0168159.ref018]\].

Materials and Methods {#sec002}
=====================

Mice {#sec003}
----

The recessive *asj* mutation was discovered at The Jackson Laboratory in 2004 in the C57BL/6J progeny of an ENU treated C57BL/6J male. The mutant strain name is C57BL/6J-*Enpp1*^*asj*^/GrsrJ and is available from The Jackson Laboratory (Stock \#012810). Experimental mice were housed in the Research Animal Facility of The Jackson Laboratory, and all procedures involving their use were approved by the Institutional Animal Care and Use Committee. The Jackson Laboratory is accredited by the American Association for the Accreditation of Laboratory Animal Care.

Genotyping the *Enpp1*^*asj*^ mutation {#sec004}
--------------------------------------

The *asj* mutation is a single nucleotide substitution of T to A in exon 7 of the *Enpp1* gene resulting in an amino acid substitution from valine to aspartic acid at residue 246 (p.V246D) of protein Reference Sequence NP_032839. The T to A point mutation (nt 848 of mRNA Reference Sequence NM_008813) creates a new *TaqI* restriction site (TCGA), which is the basis of the genotyping method described by Harris and colleagues \[[@pone.0168159.ref012]\] and that was used in this study to distinguish wild-type from mutant alleles.

Assessment of hearing by ABR {#sec005}
----------------------------

Hearing was evaluated in anesthetized (Avertin, 0.4 mg/g mouse mass) wild-type, *Enpp1*^*asj/+*^, and *Enpp1*^*asj/asj*^ mice by measuring auditory brainstem response (ABR). A computer-aided evoked potential system (Intelligent Hearing Systems) was used to measure mouse ABR thresholds as previously described \[[@pone.0168159.ref019]\].

Histological analyses of middle and inner ears {#sec006}
----------------------------------------------

Histological analyses of the middle and inner ears were performed following the methods described previously \[[@pone.0168159.ref020]\]. Briefly, middle and inner ears from *Enpp1*^*asj/asj*^ mice and wild-type mice were dissected after transcardial perfusion with Bouin's fixative. Ear samples were immersed in Bouin's fixative (7 days for one-month-old mice and 30 days for mice older than 6 months) and embedded in paraffin. Sections (7 mm) were cut and mounted onto Fisher Superfrost Plus slides (Fisher Scientific, Pittsburgh, PA) and counterstained in hematoxylin/eosin (H&E). Goblet cells, whose sole function is to secrete mucus, were identified by Mayer's Mucicarmine staining method following the protocol provided by Electron Microscopy Sciences (Catalog \#26320). The stepedial artery was dissected from 6-month-old control and mutant mice, sectioned without decalcification, and stained with Alizarin red following standard procedures \[[@pone.0168159.ref021]\].

Evaluation of pathology of middle ears {#sec007}
--------------------------------------

A scoring system of -/+/++/+++ was used to assess the severity of pathology in the middle ears following a previously described method with modifications \[[@pone.0168159.ref022]\]. Histological analysis of the middle ears of control and mutant mice was performed using an Olympus BX51 microscope. A '-' symbol was assigned when the pathology is absent in the middle ear. A '+' symbol was assigned when pathology was very scarce in the middle ear. A '++' symbol was assigned when pathology was more prevalent, but not to the point of spanning the entire middle ear. A '+++' symbol was assigned when pathology spanned the entire middle ear. The following pathologies were evaluated by this scoring system: middle ear effusion, inflammatory cell infiltration, tissue proliferation (epithelial hyperplasia), abnormal tissue at the Eustachian tube opening in the middle ear cavity, ectopic mineralization, and clusters of goblet cells.

Scanning electron microscopy (SEM) {#sec008}
----------------------------------

Middle ears from *Enpp1*^*asj/asj*^ and wild-type mice were dissected after transcardial perfusion with 4% paraformaldehyde (PFA) and then immersed in 2.5% glutaraldehyde in 0.1 M cacodylate buffer (pH = 7.2) at 4°C overnight. Dissection was performed to expose the middle ear cavities. After three 15-minute washes with cacodylate buffer (pH = 7.2) at room temperature, samples were post-fixed with the osmium-thiocarbohydrazide-osmium-thiocarbohydrazide-osmium (OTOTO) method \[[@pone.0168159.ref023]\], and dehydrated in increasing concentrations of ethanol at 4°C. Samples were critical point dried with Hexamethyldisilazane (HMDS) and then air dried in fume hood. Samples were then coated with 15nm gold and analyzed in a Hitachi S-3000 scanning electron microscope (Hitachi, Tokyo, Japan) at 20 kV.

Results {#sec009}
=======

Hearing impairment in *Enpp1*^*asj*^ mutant mice {#sec010}
------------------------------------------------

Hearing in the *Enpp1* mutant mice and age-matched controls was evaluated by ABR threshold analysis. Initial ABR measurements of three-month-old mutant mice revealed a moderate to severe hearing loss with threshold increases of 25--35 decibels (dB) compared to the normal thresholds in the control mice for both click and all pure tone stimuli (8 kHz, 16 kHz, 32 kHz). To further characterize the hearing ability of *Enpp1*^*asj/asj*^ mice and to determine whether the hearing impairment is progressive with age, recurrent ABR measurements were performed in *Enpp1*^*asj/asj*^, *Enpp1*^*asj/+*^, and *Enpp1*^*+/+*^ littermates from 3 weeks to 30 weeks of age ([Fig 1](#pone.0168159.g001){ref-type="fig"}, [Table 1](#pone.0168159.t001){ref-type="table"}, [Table 2](#pone.0168159.t002){ref-type="table"}). *Enpp1*^*asj/+*^ and *Enpp1*^*+/+*^ mice (grouped as controls) showed normal ABR thresholds even at 30 weeks of age, whereas *Enpp1*^*asj/asj*^ mice exhibited elevated thresholds by 6 weeks of age. Hearing impairment is not congenital as mutant mice had normal ABR thresholds at weaning age (3 weeks). Hearing loss in mutant mice progressed in two stages: average ABR thresholds increased by about 30--35 dB between 3 and 6 weeks of age, were relatively stable between 6 and 12 weeks, increased another 20--25 db between 12 and 18 weeks, and remained stable between 18 and 30 weeks. At 12 weeks of age, only one out of 11 *Enpp1*^*asj/asj*^ mice tested showed normal thresholds in both ears ([Table 1](#pone.0168159.t001){ref-type="table"}), giving a rough estimate of hearing loss penetrance of about 90%. No head bobbing or circling behaviors were observed in the mutant mice at all ages, indicating normal vestibular function.

![Progressive hearing loss in *Enpp1*^*asj/asj*^ mice.\
ABR threshold means are shown for *Enpp1*^*asj/asj*^ mice and littermate control mice, tested at the ages of 3 (n = 6 mutant ears/8 control ears), 6 (n = 10/10), 8 (n = 6/6), 12 (n = 22/16), 18 (n = 8/6), 26 (n = 10/8), and 30 (n = 12/14) weeks. Starting from 6 weeks of age, the mutant mice exhibit significantly higher mean ABR threshold values at all the stimulus frequencies tested (click, 8 kHz, 16 kHz, 32 kHz) compared to those of the littermate controls. Thresholds of mutant mice continue to increase with age and by 18 weeks most of the *Enpp1*^*asj/asj*^ mice are profoundly hearing impaired. The increase in 32 kHz ABR thresholds of the control mice is due to the B6 background, a strain known to exhibit age-related hearing loss starting at high frequencies. Error bars indicate standard errors of the mean.](pone.0168159.g001){#pone.0168159.g001}

10.1371/journal.pone.0168159.t001

###### ABR thresholds of *asj/asj* mutant mice

![](pone.0168159.t001){#pone.0168159.t001g}

  Mouse                                            Age     Test Age       Right Ear thresholds (db SPL)   Left Ear thresholds (dB SPL)                                 
  ------------------------------------------------ ------- ---------- --- ------------------------------- ------------------------------ ----- ----- ----- ----- ----- -----
  5729                                             3 wk    23         F   30                              30                             10    35    40    45    15    35
  **5055 [\*](#t001fn001){ref-type="table-fn"}**   3 wk    22         M   30                              40                             10    40    35    40    15    40
  5738                                             3 wk    25         M   30                              20                             10    40    30    30    10    35
  **4195 [\*](#t001fn001){ref-type="table-fn"}**   6 wk    38         M   35                              70                             50    80    75    80    60    70
  5001                                             6 wk    39         F   70                              80                             40    70    45    50    30    60
  5003                                             6 wk    39         M   60                              80                             40    80    60    90    50    70
  **4094 [\*](#t001fn001){ref-type="table-fn"}**   6 wk    41         F   70                              80                             70    70    75    80    55    70
  4098                                             6 wk    41         M   35                              70                             50    60    70    80    60    70
  3915                                             8 wk    50         F   75                              80                             50    85    70    75    40    80
  **3891 [\*](#t001fn001){ref-type="table-fn"}**   8 wk    55         F   35                              60                             35    45    75    75    55    75
  **3893 [\*](#t001fn001){ref-type="table-fn"}**   8 wk    55         M   75                              85                             75    70    75    85    70    75
  3902                                             12 wk   75         F   45                              50                             30    40    40    50    30    40
  3904                                             12 wk   75         M   65                              75                             40    70    40    40    40    50
  **3905 [\*](#t001fn001){ref-type="table-fn"}**   12 wk   75         M   30                              50                             20    40    80    85    60    90
  **3899 [\*](#t001fn001){ref-type="table-fn"}**   12 wk   75         F   60                              65                             50    70    70    85    50    65
  4038                                             12 wk   89         F   100                             90                             60    90    80    80    50    70
  4039                                             12 wk   89         F   65                              80                             40    70    80    80    50    80
  4040                                             12 wk   89         M   70                              80                             60    90    70    85    50    90
  4030                                             12 wk   101        F   90                              90                             80    90    90    90    80    90
  4033                                             12 wk   101        M   60                              80                             70    70    40    60    60    70
  4034                                             12 wk   101        M   40                              70                             50    70    70    80    50    80
  4035                                             12 wk   101        M   70                              80                             50    70    40    50    50    60
  5005                                             18 wk   123        F   95                              100                            95    100   100   100   95    100
  5007                                             18 wk   125        F   90                              100                            70    90    60    90    50    90
  5010                                             18 wk   136        F   90                              100                            70    85    80    90    80    75
  5008                                             18 wk   144        F   80                              90                             70    90    90    90    80    90
  **3884 [\*](#t001fn001){ref-type="table-fn"}**   26 wk   172        M   100                             100                            90    90    75    100   60    100
  **3885 [\*](#t001fn001){ref-type="table-fn"}**   26 wk   172        F   90                              100                            70    80    100   100   100   100
  3886                                             26 wk   172        M   100                             100                            90    90    70    85    70    60
  3906                                             26 wk   188        F   100                             100                            80    100   95    90    70    100
  3913                                             26 wk   188        M   60                              70                             40    90    60    60    30    70
  3106                                             30 wk   202        F   100                             100                            100   100   90    90    70    100
  3107                                             30 wk   202        F   100                             100                            90    100   100   100   90    100
  3283                                             30 wk   204        F   100                             100                            90    100   100   100   90    100
  3098                                             30 wk   206        F   80                              90                             80    90    50    80    40    70
  3102                                             30 wk   206        M   70                              80                             70    90    90    90    60    90
  3286                                             30 wk   223        M   80                              90                             50    100   50    80    50    100
  3290                                             30 wk   223        M   100                             100                            90    100   80    80    65    90

\* Highlighted ID numbers indicate ears were examined for pathology

10.1371/journal.pone.0168159.t002

###### ABR thresholds of +/+ or +/*asj* control mice

![](pone.0168159.t002){#pone.0168159.t002g}

  Mouse                                            Age     Test Age       Right Ear thresholds (db SPL)   Left Ear thresholds (dB SPL)                            
  ------------------------------------------------ ------- ---------- --- ------------------------------- ------------------------------ ---- ---- ---- ---- ---- ----
  5044                                             3 wk    21         F   35                              30                             20   40   40   40   20   40
  5045                                             3 wk    21         M   35                              30                             20   35   30   30   20   30
  5054                                             3 wk    22         F   35                              40                             10   30   30   30   10   30
  5056                                             3 wk    22         M   33                              30                             10   30   40   40   20   30
  **4193 [\*](#t002fn001){ref-type="table-fn"}**   6 wk    38         M   30                              30                             10   40   35   30   20   40
  5002                                             6 wk    39         F   20                              20                             10   30   40   30   15   40
  5004                                             6 wk    39         M   30                              40                             10   40   30   40   10   40
  **4095 [\*](#t002fn001){ref-type="table-fn"}**   6 wk    41         F   30                              40                             20   50   35   40   20   50
  4097                                             6 wk    41         M   30                              30                             10   40   40   30   15   30
  3914                                             8 wk    50         F   30                              40                             25   50   35   40   30   50
  3888                                             8 wk    55         F   25                              30                             20   40   35   40   20   40
  **3892 [\*](#t002fn001){ref-type="table-fn"}**   8 wk    55         M   40                              50                             25   50   40   40   10   30
  **3900 [\*](#t002fn001){ref-type="table-fn"}**   12 wk   75         F   30                              35                             10   40   30   35   20   40
  3901                                             12 wk   75         F   30                              40                             25   50   60   60   35   60
  3903                                             12 wk   75         F   25                              30                             20   40   35   30   20   40
  4036                                             12 wk   89         F   35                              30                             10   30   50   35   15   40
  4037                                             12 wk   89         F   50                              55                             35   70   35   40   20   40
  4032                                             12 wk   101        M   25                              30                             10   40   35   30   10   40
  4029                                             12 wk   101        F   35                              40                             10   40   40   40   10   40
  4031                                             12 wk   101        M   30                              40                             10   40   35   50   10   40
  5006                                             18 wk   123        F   35                              30                             10   30   35   40   20   40
  5011                                             18 wk   136        F   30                              50                             10   60   35   50   20   40
  5009                                             18 wk   144        F   35                              30                             30   60   45   30   20   80
  **3883 [\*](#t002fn001){ref-type="table-fn"}**   26 wk   172        F   40                              40                             20   80   40   50   20   60
  **3887 [\*](#t002fn001){ref-type="table-fn"}**   26 wk   172        M   40                              60                             30   70   40   60   40   50
  3910                                             26 wk   188        M   35                              30                             10   70   40   40   10   80
  3911                                             26 wk   188        F   30                              40                             20   50   40   40   20   70
  3110                                             30 wk   202        F   30                              40                             20   40   30   40   20   40
  3112                                             30 wk   202        M   30                              40                             20   50   30   40   20   50
  3286                                             30 wk   204        M   30                              30                             20   45   40   40   20   50
  3101                                             30 wk   206        M   35                              40                             20   40   45   40   30   40
  3104                                             30 wk   206        M   30                              30                             10   40   40   40   20   45
  5014                                             30 wk   231        F   40                              50                             30   80   50   40   30   90
  5012                                             30 wk   234        F   40                              50                             40   85   50   50   40   90

\* Highlighted ID numbers indicate ears were examined for pathology

Otitis media with effusion in *Enpp1*^*asj/asj*^ mice {#sec011}
-----------------------------------------------------

To assess the causes of hearing impairment in the *Enpp1*^*asj/asj*^ mice, anatomical analysis of the middle and inner ears was performed after the completion of ABR measurements. We processed the whole bullae for histological studies, which allowed us to observe both middle and inner ear morphology. We did not observe any obvious inner ear defects in the *asj* mutant mice, such as hair cell and spiral ganglion cell loss, or stria vascularis degeneration. However, we observed major histopathology in the middle and outer ear, with details described below.

### a. Middle ear effusion and epithelial proliferation in *Enpp1* mutant mice {#sec012}

All ears from *Enpp1*^*asj/asj*^ mice that had elevated ABR thresholds (n = 11) exhibited defects in the middle ear including retracted tympanic membranes and middle ear cavities filled with effusion (Figs [2](#pone.0168159.g002){ref-type="fig"} and [3](#pone.0168159.g003){ref-type="fig"}, [Table 3](#pone.0168159.t003){ref-type="table"}) and a thickened epithelium with fibrous polyps (Figs [2B, 2D](#pone.0168159.g002){ref-type="fig"} and [3C](#pone.0168159.g003){ref-type="fig"}, [Table 3](#pone.0168159.t003){ref-type="table"}). In addition, older *Enpp1*^*asj/asj*^ mice exhibited excessive accumulation of discharge in the external ear canal ([Fig 2H](#pone.0168159.g002){ref-type="fig"}). All of the ears from the control *Enpp1*^*+/asj*^ and *Enpp1*^*+/+*^ mice examined (n = 12) showed a transparent tympanic membrane, a clear middle ear cavity lined with a thin epithelium.

![Otitis media in *Enpp1*^*asj/asj*^ mice.\
A, B: Representative images of pathological changes in the middle ears of *Enpp1*^*asj*^ mutant mice (B) compared with controls (A) at the age of 5 months. The middle ear cavity (MEC) of *Enpp1*^*asj*^ mutant mice is filled with effusions (black asterisk), fibroblastic and amorphous tissue masses (long arrows), and inflammatory cells (arrow head). Ectopic mineralization of the otic capsule is also evident in mutant mice (open arrow in B). Control mice show a clear middle ear cavity without fibroblastic proliferation (A). C, D: The thickness of the middle ear epithelium (double headed arrows) is greater in *Enpp1*^*asj*^ mutant mice (D) than controls (C). E, F: The stapedial artery wall (arrows) is thicker in *Enpp1*^*asj*^ mutant mice (F) than controls (E). G, H: Representative images of discharge in mutant mice (H) and littermate controls (G) at the age of 5 months. The external ear cavity of the mutant mice is filled with discharge (red asterisk), while control mice have a clear external ear canal and easily observable tympanic membrane (black asterisk). Scale bars: A, B = 200μm, C, D = 50μm, E, F = 80 μm.](pone.0168159.g002){#pone.0168159.g002}

![Development of otitis media in *Enpp1*^*asj/asj*^ mice.\
A-D: 6--12 week time course of middle ear pathology of *Enpp1*^*asj*^ mutant mice (B, C, D) compared with a 12-week-old control (A). At 6 weeks of age (B), an aqueous effusion (black asterisk) and a slightly thickened epithelium (arrow) are observed in the middle ear cavity of the *Enpp1*^*asj*^ mutant mice. At 8 weeks (C), the middle ear cavity of the *Enpp1*^*asj*^ mutant mouse is filled with an aqueous effusion (black asterisk) and contains amorphous tissue masses (green asterisk). The middle ear epithelium is much thickened (arrow), and the otic capsule exhibits regions of ectopic mineralization (arrowhead) with adjacent fibroblastic proliferation. At 12 weeks (D), the middle ear cavity of mutant mice is filled with pus-like secretions (black asterisk), a thickened epithelium (arrows), and an amorphous tissue mass (green asterisk). E, F: Eustachian tube morphology of mutant (F) and control (E) mice at 12 weeks of age. In mutant mice, an amorphous tissue mass (green asterisk) is present near the orifice of the Eustachian tube (empty arrow), which may impede Eustachian tube function and lead to an accumulation of effusion in the middle ear cavity. G, H: Cochlear morphology and round window membranes of mutant (H) and control (G) mice. Cochlear morphology is grossly normal in *Enpp1*^*asj*^ mutant mice compared with controls; however, the round window membrane (black arrow) of mutant mice is thicker. MEC: middle ear cavity. Scale bars: A, B, C, D, E, F = 200μm, G, H = 100μm.](pone.0168159.g003){#pone.0168159.g003}

10.1371/journal.pone.0168159.t003

###### Histological assessment of the middle ears of the *Enpp1* mutant and control mice.

MEE: Middle Ear Effusion; EH: Epithelial Hyperplasia; IC: Inflammatory Cells; ETO: Eustahian Tube Opening; EM: Ectopic Mineralization; CGC: Cluster of Goblet Cells.

![](pone.0168159.t003){#pone.0168159.t003g}

  Mouse ID                                     Age    Genotype   MEE   EH    IC    ETO   EM   CGC
  -------------------------------------------- ------ ---------- ----- ----- ----- ----- ---- -----
  4012L                                        1wk    Control    \-    \+    \-    N/A   \-   \-
  4017                                         1wk    Control    \-    \-    \-    N/A   \-   \-
  4015L                                        1wk    Control    \-    \-    \-    N/A   \-   \-
  4016L                                        1wk    Mutant     \-    \-    \-    N/A   \-   \-
  4016R                                        1wk    Mutant     \-    \-    \-    N/A   \-   \-
  4018L                                        1wk    Mutant     \-    \+    \-    N/A   \-   \+
  4022L                                        2wk    Control    \-    \-    \-    N/A   \-   \-
  4022R                                        2wk    Control    \-    \-    \-    N/A   \-   \-
  4019R                                        2wk    Control    \-    \-    \-    N/A   \-   \-
  4023L                                        2wk    Mutant     \-    \+    \-    N/A   \-   \-
  4023R                                        2wk    Mutant     \-    \+    \-    N/A   \-   \-
  4020L                                        2wk    Mutant     \-    ++    \+    N/A   \-   \-
  4008L                                        2wk    Mutant     \-    \+    \-    N/A   \-   \-
  4008R                                        2wk    Mutant     \-    \+    \-    N/A   \-   \-
  4007L                                        2wk    Mutant     \-    \+    \-    N/A   \-   \+
  4007R                                        2wk    Mutant     \-    \+    \-    N/A   \-   \+
  4002L                                        3wk    Control    \-    \-    \-    N/A   \-   \-
  4002R                                        3wk    Control    \-    \-    \-    N/A   \-   \-
  4001L                                        3wk    Control    \-    \-    \-    N/A   \-   \+
  4001R                                        3wk    Control    \-    \-    \-    N/A   \-   \+
  4004L                                        3wk    Mutant     \-    \-    \-    N/A   \-   \-
  4004R                                        3wk    Mutant     \-    \-    \-    N/A   \-   \-
  4000L                                        3wk    Mutant     \-    \-    \-    N/A   \-   \-
  4000R                                        3wk    Mutant     \-    \-    \-    N/A   \-   \-
  5055R[\*](#t003fn001){ref-type="table-fn"}   3wk    Mutant     \-    \+    \-    N/A   \-   \-
  5055L[\*](#t003fn001){ref-type="table-fn"}   3wk    Mutant     \-    \+    \-    N/A   \-   \-
  4193R[\*](#t003fn001){ref-type="table-fn"}   6wk    Control    \-    \+    \-    N/A   \-   \+
  4195R[\*](#t003fn001){ref-type="table-fn"}   6wk    Mutant     \+    \-    \-    N/A   \+   \+
  4094R[\*](#t003fn001){ref-type="table-fn"}   6wk    Mutant     +++   +++   \+    N/A   \+   +++
  3892L[\*](#t003fn001){ref-type="table-fn"}   8wk    Control    \-    \-    \-    \-    \-    
  3893R[\*](#t003fn001){ref-type="table-fn"}   8wk    Mutant     +++   +++   \+    +++   \+   ++
  3891R[\*](#t003fn001){ref-type="table-fn"}   8wk    Mutant     \+    \+    \-    N/A   \+   \-
  3900R[\*](#t003fn001){ref-type="table-fn"}   12wk   Control    \-    \-    \-    N/A   \+   \-
  3905L[\*](#t003fn001){ref-type="table-fn"}   12wk   Mutant     +++   +++   ++    N/A   \+   +++
  3905R[\*](#t003fn001){ref-type="table-fn"}   12wk   Mutant     \+    \+    \+    \+    \+   \-
  3899L[\*](#t003fn001){ref-type="table-fn"}   12wk   Mutant     \+    +++   ++    +++   \+   +++
  3899R[\*](#t003fn001){ref-type="table-fn"}   12wk   Mutant     ++    +++   ++    N/A   \+   ++
  3883L[\*](#t003fn001){ref-type="table-fn"}   26wk   Control    \-    \-    \-    N/A   \-   \-
  3883R[\*](#t003fn001){ref-type="table-fn"}   26wk   Control    \-    \-    \-    \-    \-   \-
  3887L[\*](#t003fn001){ref-type="table-fn"}   26wk   Control    \-    \-    \-    N/A   \-   \+
  3887R[\*](#t003fn001){ref-type="table-fn"}   26wk   Control    \-    \-    \-    \-    \-   \-
  3884L[\*](#t003fn001){ref-type="table-fn"}   26wk   Mutant     +++   ++    ++    ++    \-   +++
  3884R[\*](#t003fn001){ref-type="table-fn"}   26wk   Mutant     \+    ++    \+    ++    \+   \+
  3885L[\*](#t003fn001){ref-type="table-fn"}   26wk   Mutant     \-    \-    \+    \-    \-   \+
  3885R[\*](#t003fn001){ref-type="table-fn"}   26wk   Mutant     ++    ++    +++   ++    \-   ++
  2094R                                        30wk   Mutant     ++    ++    ++    \+    \+   ++
  2096R                                        30wk   Mutant     +++   +++   +++   ++    \+   ++
  2098R                                        30wk   Mutant     +++   +++   ++    +++   \+   ++

\* Indicate ears with ABR data.

### b. Increased goblet cell density and mucin secretion in *Enpp1*^*asj/asj*^ mice {#sec013}

In the epithelium lining the middle ear cavity and the Eustachian tube, mucins secreted by goblet cells build the first line of defense in protecting the host from invading pathogens; movements of the cilia then help to get rid of the pathogens, with mucins serving as a lubricant \[[@pone.0168159.ref024]\]. However, when chronic inflammation is present, some of the epithelial cells transdifferentiate to mucin-secreting goblet cells \[[@pone.0168159.ref024]\]. These additional goblet cells secrete excessive mucins, which accumulate in the middle ear cavity and lead to conductive hearing loss (otitis media). We used Mayer's mucicarmine staining to detect the density of goblet cells in the *asj* mutant mice. Already at two weeks of age, an excess of goblet cells was observed around the opening of the Eustachian tube and in the Eustachian tube duct of mutant mice ([Fig 4B](#pone.0168159.g004){ref-type="fig"}). In the control mice, scattered goblet cells were seen around the opening of the Eustachian tube, but very few were detected along the Eustachian tube duct ([Fig 4A](#pone.0168159.g004){ref-type="fig"}). Similar observations were made in two-month-old adult mice: more goblet cells were present in the epithelia lining the middle ear cavity and the Eustachian tube in mutants ([Fig 4D](#pone.0168159.g004){ref-type="fig"}) than in controls ([Fig 4C](#pone.0168159.g004){ref-type="fig"}).

![Increased density of goblet cells in *Enpp1*^*asj/asj*^ mice.\
Mayer\'s mucincarmine method was used to visualize goblet cells (stained red) in the epithelia lining the Eustachian tube (A, B) and middle ear cavity (C, D) of mutant and control mice. A, B: Few goblet cells are seen in the epithelia lining the Eustachian tube of littermate control mice (A, empty arrow points to Eustachian tube, insert shows higher magnification of the Eustachian tube epithelia). By contrast, goblet cells are present at high density in the epithelium lining the Eustachian tube of *Enpp1*^*asj*^ mutant mice (B, empty arrow points to Eustachian tube, magnified inset shows goblet cells, marked by arrows, in the Eustachian tube epithelia). C, D: More goblet cells are present in the epithelia in the middle ear cavity (MEC) of the *asj* mutant mouse (arrows in D) than in the control (C). Scale bars: A, B = 200 μm, C, D = 50 μm, A and B inserts = 20 μm.](pone.0168159.g004){#pone.0168159.g004}

### c. Impaired Eustachian tube function due to epithelia proliferation {#sec014}

Out of 10 ear preparations (8--30 weeks) that allowed us to observe the opening of the Eustachian tube in the middle ear cavity, 7 had amorphous tissues that could potentially block the Eustachian tube ([Table 3](#pone.0168159.t003){ref-type="table"}) thereby disrupting middle ear pressure regulation and ciliary clearance of secretions.

### d. Impaired middle ear epithelial clearance function due to excess mucin and loss of microciliary function {#sec015}

Using scanning electron microscopy ([Fig 5](#pone.0168159.g005){ref-type="fig"}), we assessed the integrity of the mucociliary epithelium in 1-month-old and 6-month-old wild-type and *Enpp1*^*asj/asj*^ mice (n = 3 each genotype). The epithelium of one-month-old mutant mice had scattered areas with high densities of goblet cells ([Fig 5B](#pone.0168159.g005){ref-type="fig"}), which was confirmed by Mayer's mucincarmine staining. Goblet cell density in 6-month-old mutants could not be determined because of the obscuring layer of mucin ([Fig 5D](#pone.0168159.g005){ref-type="fig"}). These results indicate that excessive mucin secreted by increased numbers of goblet cells and the hindering effect of the mucin layer on ciliary function in the *asj* mutant mice are contributing factors to the occurrence of otitis media.

![Scanning electron micrographs of epithelium lining the middle ear cavity.\
Compared with littermate controls (A), the middle ear epithelium in 1-month-old *Enpp1*^*asj*^ mutant mice (B) shows an increased number of goblet cells (red asterisks). Scattered goblet cells (green asterisks) and cilia are seen in the mucociliary epithelia of control mice at 6-months of age (C); however, a layer of mucin obscures most cilia and goblet cells (arrows) in age-matched *Enpp1*^*asj*^ mutant mice (D). Scale bars = 25μm.](pone.0168159.g005){#pone.0168159.g005}

Over-calcification of middle ear structures (tympanosclerosis) {#sec016}
--------------------------------------------------------------

6-month old control mice have transparent tympanic membrane ([Fig 6A](#pone.0168159.g006){ref-type="fig"}), mutant mice at the same age have retracted tympanic membrane due to the pressure of excessive discharge and white patch were observed at pars tensa of tympanic membrane in the mutant mice ([Fig 6B](#pone.0168159.g006){ref-type="fig"}). We dissected middle ear ossicles of 6-month-old *Enpp1*^*asj/asj*^ mice with littermate controls. Control mice have normal morphology of ossicles ([Fig 6C](#pone.0168159.g006){ref-type="fig"}). We found that stapes in the mutant mice have normal morphology and are freely removable from the round window ([Fig 6D](#pone.0168159.g006){ref-type="fig"}). Although malleus an incus has relative normal morphology, these two bones are fused ([Fig 6D](#pone.0168159.g006){ref-type="fig"}). The wall of the stapedial artery, which passes through the ring of the stapes, is thicker in *Enpp1*^*asj*^ mutant mice ([Fig 2F](#pone.0168159.g002){ref-type="fig"}) than controls ([Fig 2E](#pone.0168159.g002){ref-type="fig"}). Alarin red staining indicates excessive calcium deposition in the artery wall of the mutant mice ([Fig 6F](#pone.0168159.g006){ref-type="fig"}). Therefore, enlarged and stiffened stapedial artery could potentially impede the movement of the stapes and lead to impaired sound transmission to the inner ear. We observed overossification of round window ridge in the mutant mice ([Fig 2B](#pone.0168159.g002){ref-type="fig"}, [Table 3](#pone.0168159.t003){ref-type="table"}), which may indirectly contribute to otitis media and hearing loss. We observed that the round window membrane in *Enpp1*^*asj*^ mutant mice ([Fig 3H](#pone.0168159.g003){ref-type="fig"}) was thicker than in control mice ([Fig 3G](#pone.0168159.g003){ref-type="fig"}).

![Calcification of middle ear structures (or tympanosclerosis) in *Enpp1*^*asj/asj*^ mice.\
In the control mice (A), the outer ear canal is clear without any discharge. The tympanic membrane appears to be transparent and malleus (blue asterisk) is clearly visible. In the age matched mutant mice (B), surrounding bone must be removed to expose the tympanic membrane, most of which is completely covered by discharge. White patches (inside black dashed lines) were observed on the tympanic membrane of the mutant mice (B). The ossicle bones of the age matched control and mutant mice appear to have similar morphology (C-D), but malleus and incus are fused in the mutant mice (D, red arrow). M: Malleus; I: Incus; S: Stapes. Alizarin red staining reveals extensive mineralization in the stapedial artery wall (green asterisk) in *Enpp1*^*as/asjj*^ mice (F), but not in the control mice (E).](pone.0168159.g006){#pone.0168159.g006}

Bacterial infection does not play a role in the development of otitis media in *Enpp1*^*asj/asj*^ mice {#sec017}
------------------------------------------------------------------------------------------------------

The effusion was confined within the middle ear cavity and did not appear to extend through the round window into the inner ear. To detect if otitis media in the *asj* mutant mice was caused by bacterial infection, we performed gram staining in the freshly prepared middle ear sections. We failed to detect any pathogens from the middle ear cavities of the *asj* mutant mice (data not shown), suggesting a non-infection origin of the otitis media in the *asj* mutant mice.

Discussion {#sec018}
==========

Otitis media-related ear pathology of *Enpp1*^*asj*^ mutant mice {#sec019}
----------------------------------------------------------------

Beginning at 6 weeks of age, an effusion starts to appear in the middle ears of *asj* mutant mice, and moderate epithelial proliferation is observed lining the middle ear cavity. The degree of middle ear effusion and epithelial thickening in *asj* mutant mice correlates with ABR thresholds. At 12 weeks of age the content of the effusion changes from serous to suppurative, with a corresponding increase in ABR thresholds. These effusions in the middle ear cavity may interfere with the normal vibration of the tympanic membrane and movement of the ossicle chain; with suppurative effusion having a much stronger effect. We observed discharge in the outer ear cavity starting around 4 months of age. All of the ears examined from seven 6\~7-month-old *asj* mutant mice showed complete blockage of the outer ear canal by discharge, which could explain the secondary increase in ABR thresholds that occurs in *asj* mutant mice between 12 and 18 weeks of age.

Mucins are secreted by goblet cells that lay scattered in the epithelium of digestive, respiratory, urinary, and reproductive tracts either at a basal level or at a high level upon stimulation \[[@pone.0168159.ref025]\]. Mucins, together with the cilia that line the epithelia, protect the host by cleaning invading pathogens. A similar mechanism is applied by the middle ear mucociliary system to clear middle ear effusions \[[@pone.0168159.ref024]\]. Disturbed phosphate homeostasis can cause systematic inflammation. Inflammation within the middle ear cavity triggers secretion of mucin into the middle ear cavity and transdifferentiation of more epithelial cells into goblet cells, which lead to excessive effusion accumulation in the middle ear cavity. Continued chronic middle ear inflammation leads to tissue destruction and fibrosis. Thickened middle ear epithelia or fibrosis of epithelia, especially the epithelia around the opening of the Eustachian tube in the middle ear cavity can block the Eustachian tube and facilitate effusion accumulation. Although we don't have supporting evidence, excessive discharge in the outer ear canal might be caused by inflammation in the external ear. Defective action of the cilia lining the middle ear epithelia is often associated with development of otitis media, as seen in patients with primary ciliary dyskinesia (PCD) \[[@pone.0168159.ref026]\]. Impaired mucociliary function and increased number of goblet cells in the middle ear cavity of the *asj* mutant mice, confirmed by SEM and Mayer's mucicarmine staining, indicate that the middle ears of the *asj* mutant mice cannot maintain their ability to clear effusion, which therefore leads to conductive hearing loss. Overall, middle ear inflammation with effusion, amorphous tissue mass in the middle ear cavity, excessive discharge in the outer ear canal, and ectopic mineralization contribute to the conductive hearing loss in the *asj* mutant mice.

Mineralization disorders and conductive hearing loss in *Enpp1*^*asj/asj*^ mice {#sec020}
-------------------------------------------------------------------------------

Mineralization disorders due to abnormal phosphate levels have been associated with inflammation in several different diseases, including chronic kidney disease \[[@pone.0168159.ref027],[@pone.0168159.ref028]\] and caridiovascular disease \[[@pone.0168159.ref029]\]. *Enpp1*^*asj*^ adds to a growing list of mouse mutations causing phosphate homeostasis disorders that have associated conductive hearing loss, including mutations of the *Ank*, *Phex*, *Rpl38*, and *Fgf23* genes. *Ank* (progressive ankylosis) encodes a multiple-pass transmembrane protein that regulates pyrophosphate levels, and *Ank* mutant mice were reported to have middle ear ossicle fusions and associated conductive hearing loss \[[@pone.0168159.ref030]\]. *ANK* mutations in human patients also have been reported with associated with conductive hearing loss \[[@pone.0168159.ref031]\]. PHEX (X-linked phosphate regulating endopeptidase) is an enzyme that is involved in regulating the balance of phosphate in the body. *PHEX* mutations are associated with X-linked hypophosphatemic rickets in human patients, with hearing loss as one of the symptoms \[[@pone.0168159.ref032]--[@pone.0168159.ref034]\]. Mice with *Phex* mutations exhibit hypophospatemia-related abnormalities and hearing impairment \[[@pone.0168159.ref035]\], which recently was shown to be associated with middle ear effusion and ciliary defects \[[@pone.0168159.ref008]\]. *Rpl38* (ribosomal protein L38) is not known to be directly involved in phosphate regulation; however, elevated organic phosphate levels in *Rpl38*^*Ts*^ mutant mice \[[@pone.0168159.ref004]\] suggest a potential but unknown function of *Rpl38* in phosphate homeostasis. *Rpl38*^*Ts*^ mutant mice have conductive hearing loss caused by ectopic ossification and cholesterol crystal deposition in the middle ear cavity, enlarged Eustachian tube, and chronic inflammation with effusion \[[@pone.0168159.ref004]\]. FGF23 (fibroblast growth factor 23) is a circulating hormone that controls phosphate and calcium homeostasis and bone mineralization. Abnormal serum levels of FGF23 lead to systemic pathologies in humans, including renal phosphate wasting diseases and hyperphosphatemia. FGF23-deficient mice show a mixed hearing loss and middle ear malformations \[[@pone.0168159.ref036]\], and changes in circulating FGF23 have been observed in humans and mice with ENPP1 and PHEX deficiencies \[[@pone.0168159.ref016],[@pone.0168159.ref037]\].

ENPP1 produces inorganic pyrophosphate (PPi), an inhibitor of mineralization. Because PPi levels are markedly reduced in *Enpp1*^*asj/asj*^ mice \[[@pone.0168159.ref013]\], it is not surprising to see ectopic mineralization and calcification of middle ear tissues, as was observed in other soft tissues of these mutant mice \[[@pone.0168159.ref013]\]. Calcification of soft tissues within the middle ear cavity could contribute in various ways to the conductive hearing loss of *Enpp1*^*asj/asj*^ mice. The stapedial artery is an embryonic artery that disappears at the early embryo stage in humans but is conserved in mice through adult ages \[[@pone.0168159.ref038]\]. We observed a thickened stapedial artery wall in *Enpp1*^*asj*^ mutant mice, which is likely due to calcification as has been observed in other soft tissues. The thicker arterial wall is not likely to affect transport function, but because the artery passes through the ring of the stapes, its thickened wall could potentially impede the vibration of the stapes and contribute to the conductive hearing loss of mutant mice.

Abnormal mineralization can also cause otosclerosis and tympanosclerosis, two conditions that commonly lead to hearing loss in human patients. Disruption of bone homeostasis of the otic capsule can lead to otosclerosis \[[@pone.0168159.ref039]\], and the most common feature of otosclerosis is stapes fixation. Although we observed ectopic mineralization and bone deposition in the otic capsule of *asj* mutant mice starting from around 6 weeks of age, stapes fixation is absent from *Enpp1* mutant mice. Instead, we observed white patch on the tympanic membrane, malleus and incus fusion, which are typical symptoms of tympanosclerosis. We observed a thickened round window membrane in *Enpp1*^*asj/asj*^ mice at 8 weeks of age, which may increase the rigidity of the membrane and impede proper cochlear fluid movement and hair cell stimulation \[[@pone.0168159.ref040]\]. Therefore, *Enpp1*^*asj*^ mice can serve as a model for studying tympanosclerosis.

Decreased PPi levels in *Enpp1*^*asj/asj*^ mice also lead to otitis media, perhaps the most important factor contributing to the hearing loss, but the underlying mechanism of pathology is uncertain. ENPP1 deficiency is known to cause elevated serum levels of FGF23 in *Enpp1* mutant mice \[[@pone.0168159.ref016]\], and excess FGF23 secreted in the middle ear may trigger mucoperiosteum proliferation, which may contribute to the development of otitis media. In support of this possibility, mucoperiosteum proliferation in *Enpp1*^*asj/asj*^ mice is remarkably enhanced around the regions of the otic capsule that exhibit ectopic mineralization. *Enpp1*^*asj*^ mice provide a tool to unravel the underlying mechanism of the development of otitis media that is associated with abnormal phosphate homeostasis.

This is the first report of hearing loss and ear pathology associated with a mutation of the mouse *Enpp1* gene. The conductive hearing loss of *Enpp1*^*asj*^ mutant mice provides a new animal model for studying otitis media and tympanosclerosis related to mineralization defects. It also provides a specific model for understanding the hearing loss recently reported to be a clinical feature associated with human *ENPP1* mutations \[[@pone.0168159.ref017],[@pone.0168159.ref018]\].
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